Summary
Stryker Corporation reported solid revenue growth in the second quarter of 2022, with net sales increasing by 4.6% year-over-year to $4.49 billion, reaching $8.77 billion for the first six months of the year, up 6.3%. This growth was driven by increased unit volume across both the MedSurg and Neurotechnology and Orthopaedics and Spine segments, although foreign currency headwinds impacted reported international sales. The company also completed a significant acquisition of Vocera Communications for approximately $2.6 billion, strengthening its Medical business within the MedSurg segment and expanding its digital capabilities. Despite topline growth, operating income margin saw some pressure, with reported operating income for the quarter at $772 million (17.2% margin) compared to $732 million (17.0% margin) in the prior year, and for the six months at $1.22 billion (13.9% margin) versus $1.19 billion (14.4% margin) in the prior year. This margin compression was attributed to inflationary pressures, supply chain challenges, and increased R&D investments. Financially, Stryker ended the quarter with $1.04 billion in cash and cash equivalents, a decrease from the prior year-end, largely due to investing activities related to the Vocera acquisition and increased inventory levels to manage supply chain issues. The company also managed its debt effectively, issuing a $1.5 billion term loan in February 2022. Management highlighted ongoing efforts to navigate macroeconomic challenges, including inflation and supply chain disruptions, while continuing to invest in product development and strategic acquisitions. The company remains focused on its core business segments and is optimistic about the recovery of elective procedures.
Financial Highlights
50 data points| Revenue | $4.49B |
| Cost of Revenue | $1.67B |
| Gross Profit | $2.83B |
| R&D Expenses | $351.00M |
| SG&A Expenses | $1.54B |
| Operating Expenses | $2.05B |
| Operating Income | $772.00M |
| Net Income | $656.00M |
| EPS (Basic) | $1.73 |
| EPS (Diluted) | $1.72 |
| Shares Outstanding (Basic) | 378.30M |
| Shares Outstanding (Diluted) | 382.20M |
Key Highlights
- 1Net sales increased by 4.6% to $4.49 billion in Q2 2022 and by 6.3% to $8.77 billion for the first six months of 2022, driven by volume increases.
- 2Completed the acquisition of Vocera Communications for approximately $2.6 billion, enhancing the MedSurg and Neurotechnology segment's digital care coordination capabilities.
- 3Operating income margin faced pressure due to inflationary pressures and supply chain challenges, leading to adjusted operating income margin contracting by 220 basis points in Q2 and 190 basis points for the six months.
- 4Research, Development, and Engineering (R&D) expenses increased significantly, up 13.2% for the quarter and 27.8% for the six months, reflecting continued investment in innovation and integration of acquisitions.
- 5Recall charges decreased substantially to $4 million in Q2 2022 and $18 million for the six months, compared to $76 million and $82 million respectively in the prior year, primarily related to legacy hip products.
- 6The company ended the period with $1.04 billion in cash and cash equivalents, with a notable shift in geographic cash holdings towards international locations (55% of cash as of June 30, 2022).
- 7The company issued a $1.5 billion term loan in February 2022 to fund the Vocera acquisition and has seen a significant decrease in recall-related charges.